Nebido (Testosterone Undecanoate)

Testosterone undecanoate is a long‑acting ester that, after intramuscular injection, is slowly hydrolysed to free testosterone. The released hormone binds to androgen receptors throughout the body, influencing gene expression and producing anabolic and androgenic effects that replace the missing natural hormone.

The specific dose and dosing interval of Nebido are determined by the prescribing healthcare professional based on the patient’s clinical condition, testosterone levels, and response to therapy. Typical regimens involve an intramuscular injection administered every 10 to 14 weeks, but exact scheduling is individualized.

Nebido is not indicated for use in women, and its safety during pregnancy or lactation has not been established. It is contraindicated in pregnant or nursing women, and women of child‑bearing potential should avoid exposure and use effective contraception if treatment is considered.

To order Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nebido offers a long‑acting injectable formulation that requires fewer administrations (typically every 10‑14 weeks) compared with shorter‑acting testosterone esters that may need weekly or bi‑weekly injections. This reduced injection frequency can improve patient convenience and adherence while providing stable serum testosterone levels.

Nebido should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use, and follow aseptic techniques when preparing the injection to maintain sterility.

Nebido is given as an intramuscular injection, usually into the gluteal muscle. The injection must be performed by a qualified healthcare professional using aseptic technique. The volume and concentration are determined by the prescriber, and the injection site should be rotated as advised.

Serious risks include polycythemia (elevated red blood cell count), cardiovascular events such as myocardial infarction or stroke, liver enzyme abnormalities, prostate enlargement or cancer progression, severe hypertension, and allergic reactions including anaphylaxis. Patients should be monitored regularly for these conditions.

Nebido is contraindicated in men with known hypersensitivity to testosterone undecanoate or any formulation component, those with prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or significant cardiovascular disease. Women, especially pregnant or nursing, should also avoid this medication.